Abstract

BackgroundSystemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of various autoantibodies. This disease causes disabling neuropsychiatric symptoms even in the absence of apparent inflammation in the central nervous system (CNS), but the mechanisms involved remain unknown. Innate immune-mediated inflammation has attracted attention as a pathogenic mechanism in neuropsychiatric diseases.MethodsWe investigated the CNS of lupus-prone mice focusing on innate immunity. Three strains of lupus-prone mice, FcγRIIB−/−Yaa, an F1 hybrid of NZB and NZW (NZB/NZW) mice, and MRL/Faslpr (MRL/lpr) mice were used to analyze CNS immunopathology.ResultsFlow cytometry analysis demonstrated the numbers of brain CD45+ cells were increased compared with controls in lupus-prone mice. Upregulation of MHC class I and PDCA1 was observed in microglia and CD11b+ myeloid cells of lupus-prone mice, indicating they were activated in response to interferons (IFN). Microglial gene expression analysis of FcγRIIB−/−Yaa mice revealed the upregulation of IFN-responsive genes and inflammation-related genes including Axl, Clec7a, and Itgax, which were previously reported in neurodegenerative conditions and primed conditions. Upregulated chemokine gene expressions including Ccl5 and Cxcl10 were concurrent with increased numbers of T cells and monocytes, especially Ly6Clo monocytes in the CNS. Upregulation of Axl, Clec7a, Itgax, Ccl5, and Cxcl10 was also observed in NZB/NZW mice, indicating common lupus pathology. The primed status of microglia in FcγRIIB−/−Yaa mice was also demonstrated by morphological changes such as enlarged cell bodies with hypertrophic processes, and hyperreactivity to lipopolysaccharide. Immunohistochemistry of FcγRIIB−/−Yaa mice indicated reactive responses of astrocytes and vascular endothelium. Behavioral studies of FcγRIIB−/−Yaa mice revealed depressive-like behavior and heat hyperalgesia in the forced swim test and the tail-flick test, respectively.ConclusionsOur data indicated that microglia in lupus exhibit a unique primed phenotype characterized by the upregulated expressions of neurodegeneration-related genes and IFN-responsive genes. Interaction with peripheral cells and brain resident cells was presumed to orchestrate neuroinflammation. Targeting innate immune cells, such as microglia and monocytes, may be a promising therapeutic approach for neuropsychiatric SLE.

Highlights

  • Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of various autoantibodies

  • Even though these diseases do not exhibit clinical signs of systemic inflammation, inflammatory profiles were observed by detailed blood cytokine examinations [5, 6], and innate immunemediated inflammation in the central nervous system (CNS) characterized by microglial activation detected by positron emission tomography (PET) has been reported in both diseases [7, 8]

  • We investigated immunological changes in the CNS of three strains of lupusprone mice: FcγRIIB−/−Yaa mice, a lupus model created by the lack of FcγRIIB suppression and duplication of Toll-like receptor 7 (TLR7) by the Yaa gene [21]; an F1 hybrid between NZB and NZW (NZB/NZW) mice; and MRL/Faslpr (MRL/lpr) mice

Read more

Summary

Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of various autoantibodies. Neuropathy, seizures, and acute confusional states are attributed to autoantibodies and inflammatory mediators, and cerebrovascular diseases are caused by vascular events Symptoms such as mild forms of headache, cognitive impairment, and mood disorders are more frequently observed in SLE patients compared with control groups, they are sometimes considered not attributable to SLE [3], and their underlying mechanisms remain unclear. Symptoms such as cognitive impairment and mood disorders in SLE patients are often accompanied by fatigue and pain [4], which are the principal symptoms of fibromyalgia and myalgic encephalomyelitis/ chronic fatigue syndrome (ME/CFS) Even though these diseases do not exhibit clinical signs of systemic inflammation, inflammatory profiles were observed by detailed blood cytokine examinations [5, 6], and innate immunemediated inflammation in the central nervous system (CNS) characterized by microglial activation detected by positron emission tomography (PET) has been reported in both diseases [7, 8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call